首页> 美国卫生研究院文献>3 Biotech >Precursor-directed combinatorial biosynthesis of cephalosporin analogue by endolithic actinobacterium Streptomyces sp. AL51 by utilizing thiophene derivative
【2h】

Precursor-directed combinatorial biosynthesis of cephalosporin analogue by endolithic actinobacterium Streptomyces sp. AL51 by utilizing thiophene derivative

机译:内生放线放线菌链霉菌属的前体指导的头孢菌素类似物的组合生物合成。利用噻吩衍生物的AL51

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Natural products or their derivatives provide a reliable resource for new drugs. The multi-step chemical reaction to produce new drug is not only expensive but also release pollutants. The precursor-based combinatorial biosynthesis (PCB) is, however, a better option to produce novel natural products with potential pharmaceutical applications. The present work is an attempt to synthesize an antibacterial compound by transforming thiophene precursor using endolithic Streptomyces sp. AL51. The Streptomyces sp. AL51 was isolated from a granite rock sample collected from Mylliem, Meghalaya, India. The isolate was identified as Streptomyces sp. based on its cultural, morphological, biochemical and molecular characteristics. The bioactive compound CAx1 was extracted from the fermentation broth. The compound was characterized by bioactivity-guided fractionation and identified by infrared, UV–visible, nuclear magnetic resonance and mass spectrometry data and identified as 7-[1-(thiophene-5-yl)-1-formamido]-3-propylenyl-3-cephem-4-carboxylic acid with molecular formula C15H14N2O4S2. The purified compound showed considerable in vitro antibacterial activity against both Gram-positive and Gram-negative bacteria showing its broad spectrum property. The obtained results provide promising baseline information for the potential use of endolithic actinobacterium for semisynthetic drug discovery. This is the first report on PCB of broad range antibacterial compound by endolithic Streptomyces strain.Electronic supplementary materialThe online version of this article (10.1007/s13205-017-1051-8) contains supplementary material, which is available to authorized users.
机译:天然产物或其衍生物为新药提供了可靠的资源。生产新药的多步化学反应不仅昂贵,而且还会释放污染物。然而,基于前体的组合生物合成(PCB)是生产具有潜在药物应用潜力的新型天然产物的更好选择。本工作是通过使用内在链霉菌属菌种通过转化噻吩前体来合成抗菌化合物的尝试。 AL51。链霉菌AL51是从印度梅加拉亚邦Mylliem的花岗岩样品中分离出来的。该分离物被鉴定为链霉菌。基于其文化,形态,生化和分子特征。从发酵液中提取生物活性化合物CAx1。该化合物的特征在于生物活性指导的分级分离,并通过红外,可见光,核磁共振和质谱数据鉴定,并鉴定为7- [1-(噻吩-5-基)-1-甲酰胺基] -3-丙烯基-分子式为C15H14N2O4S2的3-cephem-4-羧酸。纯化的化合物对革兰氏阳性和革兰氏阴性细菌均显示出相当大的体外抗菌活性,显示出其广谱特性。所获得的结果为潜在使用内生放线放线菌用于半合成药物发现提供了有希望的基线信息。这是关于内生链霉菌菌株广泛抗菌化合物的PCB的首次报道。电子补充材料本文的在线版本(10.1007 / s13205-017-1051-8)包含补充材料,可供授权用户使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号